Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akoya Biosciences (AKYA)
NASDAQ:AKYA
Akoya Biosciences (AKYA) Stock Price & Analysis
127 Followers
AKYA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.88 - $7.47
Previous Close$2.41
Volume10.31K
Average Volume (3M)354.81K
Market Cap
$117.79M
Enterprise Value$142.63M
Total Cash (Recent Filing)$61.58M
Total Debt (Recent Filing)$85.19M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
Aug 05, 2024EPS Estimate
-$0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.47
Shares Outstanding49,386,247
10 Day Avg. Volume340,673
30 Day Avg. Volume354,806
Standard Deviation0.17
R-Squared0.15
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)-52.08
Price to Sales (P/S)4.40
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.52
Enterprise Value/Gross Profit1.74
Enterprise Value/Ebitda-2.93
Forecast
1Y Price Target
$6.08Price Target Upside154.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Akoya Biosciences News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAkoya is trading at just 1.2x this year’s revenue, a steep discount to its industry peers which trade at a median multiple of 1.9x, indicating potential for stock price appreciation.
Market PositionAkoya Biosciences is a leading provider of tools for spatial biology and is well-positioned in the early days of adoption in this market.
Strategic CollaborationsAkoya's collaboration with Shanghai KR Pharmtech enabled regulatory approval of the PhenoImager HT in China, opening up significant market opportunities.
Bears Say
OutlookAfter a disappointing 1Q24 performance, analysts are more cautious about Akoya's near-term outlook.
RevenueTotal product revenue of $12.1M (-22% y/y) came in below expectations and included Instrument revenue of $4.9M (-49% y/y).
Sales PerformanceElongated sales cycles, clinical trial milestone pushouts, and disruption from the COE reagent manufacturing transition drive significant 1Q miss.
---
Ownership Overview
39.12% Insiders
5.70% Mutual Funds
5.60% Other Institutional Investors
49.58% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AKYA FAQ
What was Akoya Biosciences’s price range in the past 12 months?
Akoya Biosciences lowest stock price was $1.88 and its highest was $7.47 in the past 12 months.
What is Akoya Biosciences’s market cap?
Currently, no data Available
When is Akoya Biosciences’s upcoming earnings report date?
Akoya Biosciences’s upcoming earnings report date is Aug 05, 2024 which is in 17 days.
How were Akoya Biosciences’s earnings last quarter?
Akoya Biosciences released its earnings results on May 13, 2024. The company reported -$0.48 earnings per share for the quarter, missing the consensus estimate of -$0.289 by -$0.191.
Is Akoya Biosciences overvalued?
According to Wall Street analysts Akoya Biosciences’s price is currently Undervalued.
Does Akoya Biosciences pay dividends?
Akoya Biosciences does not currently pay dividends.
What is Akoya Biosciences’s EPS estimate?
Akoya Biosciences’s EPS estimate is -$0.27.
How many shares outstanding does Akoya Biosciences have?
Akoya Biosciences has 49,386,246 shares outstanding.
What happened to Akoya Biosciences’s price movement after its last earnings report?
Akoya Biosciences reported an EPS of -$0.48 in its last earnings report, missing expectations of -$0.289. Following the earnings report the stock price went down -29.612%.
Which hedge fund is a major shareholder of Akoya Biosciences?
Among the largest hedge funds holding Akoya Biosciences’s share is Fisher Asset Management LLC. It holds Akoya Biosciences’s shares valued at N/A.
---
Akoya Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.08 (154.93% Upside)
$6.08 (154.93% Upside)
Blogger Sentiment
Bullish
AKYA Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.81%
12-Months-Change
Fundamentals
Return on Equity
-181.72%
Trailing 12-Months
Asset Growth
0.29%
Trailing 12-Months
Company Description
Akoya Biosciences
Akoya Biosciences Inc is an an innovative life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery and clinical research. It offers the most comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications.
---
AKYA Earnings Call
Q1 2024
0:00 / 0:00
---
AKYA Stock 12 Month Forecast
Average Price Target
$6.08
▲(154.93% Upside)
Technical Analysis
Best Analysts Covering AKYA
1 Year
1 Year Success Rate
2/10 ratings generated profit
1 Year Average Return
-27.33%
reiterated a buy rating 2 months ago
Copying Tejas Savant's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -27.33% per trade.
---